Mcdonald Partners LLC Sells 10,718 Shares of Medtronic PLC $MDT

Mcdonald Partners LLC lowered its position in Medtronic PLC (NYSE:MDT) by 74.5% in the 3rd quarter, HoldingsChannel reports. The fund owned 3,677 shares of the medical technology company’s stock after selling 10,718 shares during the period. Mcdonald Partners LLC’s holdings in Medtronic were worth $351,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in MDT. Riverbend Wealth Management LLC increased its stake in shares of Medtronic by 3.2% in the third quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company’s stock worth $332,000 after purchasing an additional 107 shares in the last quarter. Holistic Financial Partners lifted its stake in shares of Medtronic by 3.0% during the 3rd quarter. Holistic Financial Partners now owns 3,697 shares of the medical technology company’s stock valued at $352,000 after buying an additional 109 shares in the last quarter. Wynn Capital LLC boosted its holdings in Medtronic by 2.4% in the 3rd quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock worth $442,000 after buying an additional 110 shares during the period. Meridian Investment Counsel Inc. grew its stake in Medtronic by 0.4% in the 3rd quarter. Meridian Investment Counsel Inc. now owns 28,268 shares of the medical technology company’s stock valued at $2,692,000 after buying an additional 110 shares in the last quarter. Finally, Saxony Capital Management LLC grew its stake in Medtronic by 3.8% in the 3rd quarter. Saxony Capital Management LLC now owns 3,046 shares of the medical technology company’s stock valued at $290,000 after buying an additional 112 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.26% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on MDT. Leerink Partners dropped their target price on Medtronic from $120.00 to $119.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 18th. Royal Bank Of Canada boosted their price objective on Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, November 19th. Daiwa Securities Group dropped their price objective on Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, February 27th. UBS Group restated a “neutral” rating and issued a $104.00 target price on shares of Medtronic in a research note on Wednesday, February 4th. Finally, Truist Financial decreased their price target on Medtronic from $107.00 to $103.00 and set a “hold” rating on the stock in a research report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and a consensus target price of $110.74.

Medtronic Price Performance

NYSE:MDT opened at $95.58 on Thursday. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33. The stock has a fifty day moving average of $98.89 and a 200 day moving average of $96.98. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The firm has a market capitalization of $122.71 billion, a price-to-earnings ratio of 26.62, a P/E/G ratio of 2.43 and a beta of 0.71.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. The firm had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).